Table 2.

Ki-67 index variability and WHO class change in patients with multiple pathology specimens

Patient #	Primary tumor site Site1#	Metastatic/Re-biopsy tumor site Site2#	Ki-67 index (%)		Survival time	WHO class change
			Site1#	Site2#
1	pancreas	peritoneum	70	70	12	–
2	pancreas	lymph node	10	30	15	G2 → G3
3	pancreas	peritoneum	5	20	6	G2 → G2
4	pancreas	liver	5	5	11	–
5	pancreas	liver	2	2	12	–
6	pancreas	pancreas	1	1	24	–
7	pancreas	liver	1	1	38	–
8	rectum	lymph node	70	70	12	–
9	rectum	liver	50	80	16	G3 → G3
10	rectum	liver	2	5	13	G1 → G2
11	rectum	liver	2	1	5	G1 → G1
12	rectum	liver	2	5	3	G1 → G2
13	rectum	lymph node	70	90	8	G3 → G3
14	rectum	lymph node	2	5	7	G1 → G2
15	rectum	liver	2	2	14	–
16	rectum	liver	10	10	–	–
17	rectum	rectum	80	60	12	G3 → G3
18	rectum	lymph node	60	80	–	G3 → G3
19	stomach	lymph node	2	5	12	G1 → G2
20	stomach	lymph node	60	80	14	G3 → G3
21	stomach	liver	1	1	24	–
22	stomach	lymph node	60	40	22	G3 → G3
23	stomach	lymph node	5	5	27	–
24	stomach	stomach	50	80	–	G3 → G3
25	stomach	stomach	70	30	33	G3 → G3
26	stomach	stomach	30	40	21	G3 → G3
27	stomach	pancreas	70	70	8	–
28	stomach	stomach	5	5	60	–
29	ileocecal junction	lymph node	70	70	16	–
30	duodenum	liver	5	5	12	–